Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
This NIH R01 supports research institutions and investigators studying how to design rigorous clinical trials of rapid-acting psychotropic drugs (RAPIDs) and adjunctive psychosocial interventions. …
- Deadline
- Oct 11, 2026
- Posted
- Apr 29, 2026
- Award amount
- Amount not specified
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Oct 11, 2026 so you have time to apply.
In plain English
This NIH R01 supports research institutions and investigators studying how to design rigorous clinical trials of rapid-acting psychotropic drugs (RAPIDs) and adjunctive psychosocial interventions. A clinical trial is required, so applicants must be prepared to run one. Foreign (non-U.S.) organizations, foreign components of U.S. organizations, and foreign components generally are not eligible or allowed. The notice does not state an award ceiling; refer to the NOFO for eligibility and budget details.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
About this grant
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Alcohol Health Services Research (R34 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Alcohol Health Services Research (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due in 17 days
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
National Institutes of Health · Amount varies · Due in 17 days
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.